For example, pre-existing PARPi resistance in leukemia cells could be addressed by combining inhibitors of PARP and TGFβR kinase (to re-sensitize leukemia cells in the BMM [35]), inhibitors of PARP and TET2 dioxygenase (to re-sensitize leukemias carrying DNMT3A mutations [85]) and inhibitors of PARP and OTK (FLT3(ITD), JAK2(V617F), c-KIT(N822K), EGFR, IGF-1R [27,28,29,30,31]). This evidence concerns the gene JAK2 and leukemia.